Literature DB >> 17572168

Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?

Ian R Reid1, Mark J Bolland, Andrew B Grey.   

Abstract

Osteonecrosis of the jaw (ONJ) is a complication of high-dose bisphosphonate use, characterized by the finding of exposed bone in the oral cavity. It has been assumed that the primary lesion lies in bone and is related to over-suppression of bone turnover, but it is unclear why such a lesion should present with loss of the soft tissue covering of the mandible or maxilla as the primary clinical feature. A possible explanation of this paradox is that bisphosphonate is accumulated in bone in concentrations sufficient to be directly toxic to the oral epithelium. This would result in the failure of healing of soft tissue lesions (such as those caused by invasive dental procedures or by subclinical trauma from dentures) leading to secondary infection of the underlying bone. This model would explain why bone resection is unhelpful in managing this problem, suggests that low bone turnover caused by non-bisphosphonate drugs should not cause the same problem, and raises the possibility that agents which reverse bisphosphonate effects in vitro might have a role in the management of ONJ.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17572168     DOI: 10.1016/j.bone.2007.04.196

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  94 in total

Review 1.  Osteonecrosis of the jaw induced by clodronate, an alkylbiphosphonate: case report and literature review.

Authors:  Sabrina Crépin; Marie-Laure Laroche; Bernard Sarry; Louis Merle
Journal:  Eur J Clin Pharmacol       Date:  2010-05-01       Impact factor: 2.953

Review 2.  Osteonecrosis of the jaw and bisphosphonates in cancer: a narrative review.

Authors:  Cesar A Migliorati; Joel B Epstein; Elliot Abt; James R Berenson
Journal:  Nat Rev Endocrinol       Date:  2010-11-16       Impact factor: 43.330

3.  Bisphosphonates induce senescence in normal human oral keratinocytes.

Authors:  R H Kim; R S Lee; D Williams; S Bae; J Woo; M Lieberman; J-E Oh; Q Dong; K-H Shin; M K Kang; N-H Park
Journal:  J Dent Res       Date:  2011-03-22       Impact factor: 6.116

4.  Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons.

Authors:  Toshiyuki Yoneda; Hiroshi Hagino; Toshitsugu Sugimoto; Hiroaki Ohta; Shunji Takahashi; Satoshi Soen; Akira Taguchi; Satoru Toyosawa; Toshihiko Nagata; Masahiro Urade
Journal:  J Bone Miner Metab       Date:  2010-03-24       Impact factor: 2.626

5.  New evidence on bisphosphonate related osteonecrosis of the jaws suggests dental referral prior to commencement of treatment.

Authors:  A Kyrgidis; St Triaridis; K Vahtsevanos
Journal:  Hippokratia       Date:  2009-01       Impact factor: 0.471

Review 6.  Pathologic fractures in bisphosphonate-related osteonecrosis of the jaw-review of the literature and review of our own cases.

Authors:  Sven Otto; Christoph Pautke; Sigurd Hafner; Ronny Hesse; Lea Franziska Reichardt; Gerson Mast; Michael Ehrenfeld; Carl-Peter Cornelius
Journal:  Craniomaxillofac Trauma Reconstr       Date:  2013-05-31

7.  Influence of bisphosphonates on endothelial cells, fibroblasts, and osteogenic cells.

Authors:  C Walter; M O Klein; A Pabst; B Al-Nawas; H Duschner; T Ziebart
Journal:  Clin Oral Investig       Date:  2009-03-18       Impact factor: 3.573

8.  The Effectiveness of the Low-Level Laser, Antibiotic and Surgical Therapy in the Treatment of Medication-Related Osteonecrosis of the Jaws: A Case Report.

Authors:  Maria Del Pilar Rodríguez-Sánchez; Cristian Statkievicz; João Martins de Mello-Neto; Luan Felipe Toro; Ana Paula Farnezzi Bassi; Valdir Gouveia Garcia; Letícia Helena Theodoro; Edilson Ervolino
Journal:  J Lasers Med Sci       Date:  2020-01-18

9.  Does regular zoledronic acid change the bone turnover of the jaw in men with metastatic prostate cancer: a possible clue to the pathogenesis of bisphosphonate related osteonecrosis of the jaw?

Authors:  Oliver Ristow; Carlos Gerngroß; Markus Schwaiger; Bettina Hohlweg-Majert; Melanie Ristow; Steffen Koerdt; Roswitha Schuster; Sven Otto; Christoph Pautke
Journal:  J Cancer Res Clin Oncol       Date:  2014-01-28       Impact factor: 4.553

10.  Short-term effect of zoledronic acid upon fracture resistance of the mandibular condyle and femoral head in an animal model.

Authors:  Fabio Camacho-Alonso; Pía López-Jornet; Ascensión Vicente-Hernández
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2013-05-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.